EYEG EyeGate Pharmaceuticals, Inc. Stock Quote

publish chart | save to portfolio | create alert

EYEG [NASD]

EyeGate Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	3.00%	Shs Outstand	4.55M	Perf Week	-1.33%
Market Cap	15.91M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	0.00%	Shs Float	4.44M	Perf Month	-6.59%
Income	-8.40M	PEG	-	EPS next Q	-0.35	Inst Own	41.00%	Short Float	0.21%	Perf Quarter	-18.86%
Sales	0.00M	P/S	-	EPS this Y	51.20%	Inst Trans	-2.74%	Short Ratio	0.48	Perf Half Y	-35.50%
Book/sh	1.31	P/B	2.55	EPS next Y	20.00%	ROA	-78.80%	Target Price	-	Perf Year	-56.75%
Cash/sh	0.61	P/C	5.49	EPS next 5Y	-	ROE	-112.80%	52W Range	3.20 - 12.89	Perf YTD	-66.72%
Dividend	-	P/FCF	-	EPS past 5Y	11.50%	ROI	-109.20%	52W High	-74.13%	Beta	1.17
Dividend %	-	Quick Ratio	3.80	Sales past 5Y	-	Gross Margin	-	52W Low	4.22%	ATR	0.15
Employees	10	Current Ratio	3.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.27	Volatility	3.36% 4.65%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	61.60%	Profit Margin	-	Rel Volume	0.16	Prev Close	3.44
Shortable	Yes	LT Debt/Eq	0.05	Earnings	-	Payout	-	Avg Volume	19.58K	Price	3.33
Recom	2.00	SMA20	-1.81%	SMA50	-8.57%	SMA200	-27.62%	Volume	3,080	Change	-3.06%

Nov-12-20

Reiterated

H.C. Wainwright

Buy

$12 → $10

Feb-06-18

Reiterated

H.C. Wainwright

Buy

$5 → $3

Apr-07-16

Initiated

Noble Financial

Buy

$10

Feb-01-16

Initiated

Rodman & Renshaw

Buy

$10

Dec-23-15

Initiated

Chardan Capital Markets

Buy

Nov-12-15

Initiated

Maxim Group

Buy

$11

Nov-09-20 04:15PM	EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
Sep-28-20 11:05AM	EYEG: Raising Target on positive pipeline progress Zacks Small Cap Research
Sep-25-20 10:48AM	How Much Does EyeGate Pharmaceuticals' (NASDAQ:EYEG) CEO Make? Simply Wall St. +6.30%
Sep-08-20 06:55AM	EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference ACCESSWIRE +5.00%
Aug-12-20 06:55AM	EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product ACCESSWIRE +31.22%
Aug-06-20 04:15PM	EyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
Jul-14-20 06:55AM	EyeGate Pharma to Proceed with PE Pivotal Study ACCESSWIRE
Jun-11-20 06:55AM	EyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging ACCESSWIRE
Jun-01-20 06:55AM	EyeGate Pharma to Present at Jefferies 2020 Virtual Healthcare Conference ACCESSWIRE
May-19-20 09:11AM	EYEG: Solid results moving towards regulatory filings later this year Zacks Small Cap Research
May-06-20 04:15PM	EyeGate Pharma Reports First Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
09:10AM	EYEG: An Active 2020 with More to Come Zacks Small Cap Research
Apr-01-20 09:04AM	Company News for Apr 1, 2020 Zacks
Mar-31-20 06:55AM	EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study ACCESSWIRE +25.30%
Mar-04-20 04:15PM	EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update ACCESSWIRE
Jan-06-20 06:55AM	EyeGate Pharma Completes Enrollment in Follow-on PE Pilot Study ACCESSWIRE
Jan-03-20 10:25AM	EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules ACCESSWIRE
Dec-31-19 09:25AM	EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules ACCESSWIRE -17.87%
Dec-17-19 06:55AM	EyeGate Pharma Receives $1.9 Million from Exercised Warrants ACCESSWIRE
Dec-02-19 06:55AM	EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study ACCESSWIRE
Nov-22-19 09:02AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., Nov. 22, 2019: TSLA, UBER, SPLK, EYEG, WKHS Benzinga +48.02%
08:37AM	EyeGate shares jump on data for eye treatment data MarketWatch
06:55AM	EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study ACCESSWIRE
Nov-14-19 10:15AM	EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch? OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020? Zacks Small Cap Research -13.43%
Nov-07-19 06:55AM	EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE
Oct-09-19 06:55AM	EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study ACCESSWIRE
06:55AM	EyeGate Pharma Completes Randomization in Pivotal Study ACCESSWIRE
Sep-30-19 06:55AM	EyeGate Enters Into Agreement for $1.9 Million Private Placement ACCESSWIRE
Sep-23-19 06:55AM	EyeGate Pharma Regains Nasdaq Listing Compliance ACCESSWIRE +9.82%
Sep-16-19 06:55AM	EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study ACCESSWIRE
Sep-03-19 06:55AM	EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference ACCESSWIRE
Aug-29-19 12:45PM	EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019 ACCESSWIRE
Aug-26-19 06:55AM	EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study ACCESSWIRE +6.35%
Aug-08-19 06:55AM	EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE -6.82%
Aug-05-19 12:21PM	A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga
09:00AM	Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study Benzinga
06:55AM	EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study ACCESSWIRE
Jul-31-19 06:55AM	EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study ACCESSWIRE
Jul-09-19 06:55AM	EyeGate Files FDA Submission to Initiate PE Pilot Study ACCESSWIRE
Jun-26-19 06:55AM	EyeGate Announces First Patient Enrolled in PRK Pivotal Study ACCESSWIRE
Jun-05-19 10:00AM	EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study Zacks Small Cap Research +5.24%
Jun-03-19 06:55AM	EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study ACCESSWIRE +23.46%
May-14-19 06:55AM	EyeGate Pharma Receives Positive Nasdaq Listing Determination ACCESSWIRE
May-08-19 04:15PM	EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE +8.72%
May-02-19 02:00PM	EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study Zacks Small Cap Research
06:55AM	EyeGate Files IDE with FDA for PRK Pivotal Study ACCESSWIRE
Mar-28-19 10:00AM	EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study Zacks Small Cap Research
Mar-26-19 06:55AM	EyeGate Confirms Path to De Novo Filing with FDA ACCESSWIRE -13.45%
Mar-01-19 04:05PM	EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update ACCESSWIRE
Jan-29-19 06:55AM	EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-16-19 06:55AM	EyeGate Pharmaceuticals Announces Meeting Date with FDA GlobeNewswire -12.35%
Nov-30-18 12:30PM	EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE? Zacks Small Cap Research
Nov-21-18 08:45AM	Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power Discovering Underlying Factors of Influence GlobeNewswire +7.57%
Nov-14-18 11:20AM	Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity ACCESSWIRE
06:50AM	Todays Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals ACCESSWIRE
Nov-13-18 04:05PM	EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +34.66%
09:50AM	4 Healthcare Stocks Investors Are Watching In November ACCESSWIRE
06:55AM	EyeGate Pharma Announces Positive Results in Second PRK Study GlobeNewswire
06:55AM	EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study GlobeNewswire
Oct-02-18 06:55AM	EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care GlobeNewswire +25.37%
Sep-28-18 11:45AM	EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints Zacks Small Cap Research -15.16%
Sep-25-18 06:55AM	EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules GlobeNewswire
Sep-24-18 06:55AM	EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies GlobeNewswire
Sep-04-18 08:31AM	EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies GlobeNewswire -14.29%
08:30AM	EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis GlobeNewswire
Aug-29-18 08:30AM	EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 08:30AM	EyeGate Announces Enrollment of First Patient in PRK Pilot Study GlobeNewswire
Aug-07-18 08:30AM	EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf GlobeNewswire -8.31%
Aug-03-18 08:30AM	EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-26-18 09:30AM	EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off Zacks Small Cap Research -7.71%
09:20AM	EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Of Zacks Small Cap Research
Jul-24-18 08:30AM	EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel GlobeNewswire +5.85%
Jul-10-18 07:45AM	Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE -5.69%
Jun-22-18 08:30AM	EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel GlobeNewswire
Jun-11-18 07:00AM	Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
May-30-18 08:30AM	EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel GlobeNewswire
May-29-18 10:35AM	EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start Zacks Small Cap Research
May-25-18 09:37PM	Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Heres How It Performed Lately Simply Wall St.
May-22-18 08:30AM	EyeGate Addresses Majority of FDAs Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel GlobeNewswire
May-16-18 04:30PM	EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd GlobeNewswire +7.71%
May-11-18 08:30AM	EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-07-18 08:11AM	Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Simply Wall St.
Apr-17-18 04:30PM	EyeGate Announces Completion of $11.25 Million Public Offering GlobeNewswire +22.41%
Apr-13-18 07:00AM	EyeGate Announces $11.25 Million Public Offering GlobeNewswire -7.31%
Apr-11-18 08:30AM	EyeGate Issued New Patent for Iontophoretic Contact Lens Technology GlobeNewswire +25.11%
Apr-09-18 08:30AM	EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel GlobeNewswire -19.32%
Apr-06-18 08:30AM	EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis GlobeNewswire +20.48%
Mar-09-18 08:30AM	EyeGate Pharma To Participate At The 30TH Annual ROTH Conference GlobeNewswire
Mar-08-18 03:31PM	EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success? Simply Wall St. +6.42%
08:30AM	EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel GlobeNewswire
Mar-02-18 04:28PM	EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-21-18 11:30AM	EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint Zacks Small Cap Research
Feb-07-18 08:30AM	EyeGate to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-05-18 10:20AM	What Spooked Eyegate Pharmaceuticals Inc Investors Today SmarterAnalyst
08:30AM	EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery GlobeNewswire
Jan-19-18 06:55PM	Should You Worry About Eyegate Pharmaceuticals Incs (NASDAQ:EYEG) CEO Pay Check? Simply Wall St.
Jan-04-18 08:30AM	EyeGate Promotes Sarah Romano to Chief Financial Officer GlobeNewswire
Jan-02-18 03:19PM	With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry? Simply Wall St.
Dec-25-17 11:54AM	ETFs with exposure to EyeGate Pharmaceuticals, Inc. : December 25, 2017 Capital Cube
Dec-19-17 08:30AM	EyeGate Awarded New U.S. Patent for Iontophoretic Delivery of Corticosteroids to the Eye GlobeNewswire

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience